BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ...

BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ...

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without ...

Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth.

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently.

Haemonetics received clearance from the Food and Drug Administration for its next-generation plasma collection system. The medical technology company said Monday that the FDA granted 510(k) clearance ...